Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00276250 · ClinicalTrials.gov registry record · Phase 2
Islet Transplantation Using Abatacept
A Phase 2 study, sponsored by Emory University.
- Completed
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT00276250 is a Phase 2 study that has completed, run by Emory University. The registered enrollment target is 5 participants.
The verdict
NCT00276250, a Phase 2 study, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
Islet transplantation in type 1 diabetics with hypoglycemic unawareness using abatacept as a part of a novel calcineurin-inhibitor-sparing immunosuppressive regimen.
Interventions
- DRUG Abatacept
- DRUG Belatacept
- DRUG Efalizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2005-12 |
| Est. Completion | 2014-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00276250
The ClinicalTrials.gov registry entry for NCT00276250 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Abatacept is the first listed.
NCT00276250 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00276250 about?
NCT00276250 is a clinical study titled "Islet Transplantation Using Abatacept". Islet transplantation in type 1 diabetics with hypoglycemic unawareness using abatacept as a part of a novel calcineurin-inhibitor-sparing immunosuppressive regimen.
What is the current status of trial NCT00276250?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2005-12. Estimated completion is 2014-12.
What interventions are being tested in trial NCT00276250?
The interventions under investigation include: Abatacept (DRUG), Belatacept (DRUG), Efalizumab (DRUG).
Who is sponsoring clinical trial NCT00276250?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.